Anti-latency CMV Antibody
Prevention of CMV reactivation/disease in CMV-seropositive transplant recipients (HSCT/SOT)
Pre-clinicalActive
Key Facts
Indication
Prevention of CMV reactivation/disease in CMV-seropositive transplant recipients (HSCT/SOT)
Phase
Pre-clinical
Status
Active
Company
About Vunthera
Vunthera is a private, preclinical-stage biotech founded in 2020, targeting the significant unmet medical need of CMV reactivation. The company's innovative strategy involves a therapeutic antibody that flags latently CMV-infected monocytes and stem cells, enabling the patient's own immune system to eliminate this reservoir. This approach has demonstrated promising ex vivo proof-of-concept and aims to enter clinical testing in transplant patients. If successful, Vunthera's therapy could transform the management of CMV by moving from suppressing reactivation to preventing it entirely.
View full company profile